Cardiovascular disease in inflammatory rheumatic diseases

被引:116
|
作者
Castaneda, Santos [1 ]
Nurmohamed, Michael T. [2 ]
Gonzalez-Gay, Miguel A. [3 ]
机构
[1] Univ Autonoma Madrid, Div Rheumatol, Hosp Princesa, IIS IP, C Diego Leon 62, Madrid 28006, Spain
[2] Vrije Univ Amsterdam Med Ctr, Amsterdam Rheumatol & Immunol Ctr, Reade POB 7057, NL-1007 MB Amsterdam, Netherlands
[3] Univ Cantabria, Epidemiol Genet & Atherosclerosis Res Grp System, Hosp Univ Marques de Valdecilla, IDIVAL,Rheumatol Div, Avda Valdecilla S-N, Santander 39008, Spain
来源
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2016年 / 30卷 / 05期
关键词
Cardiovascular disease; Cardiovascular risk factors; Cardiovascular risk assessment; Rheumatoid arthritis; Spondyloarthritis; Ankylosing spondylitis; Psoriatic arthritis; PSORIATIC-ARTHRITIS PATIENTS; CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; HIGH-DENSITY-LIPOPROTEIN; INTIMA-MEDIA THICKNESS; SERUM URIC-ACID; RISK-FACTORS; SUBCLINICAL ATHEROSCLEROSIS; ANKYLOSING-SPONDYLITIS; MYOCARDIAL-INFARCTION;
D O I
10.1016/j.berh.2016.10.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic inflammatory rheumatic diseases (IRD), including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis, are prevalent conditions worldwide, with a considerable burden on healthcare systems. They are associated with increased cardiovascular (CV) morbidity and mortality. In this review, we focused on the epidemiology, traditional CV risk factors, genetics, and the link between chronic inflammation, atherosclerosis, and CV disease. Remarkably, patients with IRD have higher vulnerability to atheromatous plaques. The risk of unstable plaques is higher in patients with rheumatoid arthritis than in controls. Active disease is a characteristic ascribed to vulnerability and rupture of plaques and a cause of thrombosis in IRD. Management of CV risk in patients with IRD includes optimal control of disease activity. CV risk stratification by applying risk charts is also essential. Imaging techniques might be useful to determine the actual CV risk of patients with IRD who are included in the category of intermediate or moderate CV risk. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:851 / 869
页数:19
相关论文
共 50 条
  • [21] Metabolic abnormalities in patients with inflammatory rheumatic diseases
    Dessein, Patrick H.
    Solomon, Ahmed
    Hollan, Ivana
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2016, 30 (05): : 901 - 915
  • [22] Atherosclerotic Cardiovascular Risk Stratification in the Rheumatic Diseases: An Integrative, Multiparametric Approach
    Misra, Durga Prasanna
    Hauge, Ellen M.
    Crowson, Cynthia S.
    Kitas, George D.
    Ormseth, Sarah R.
    Karpouzas, George A.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2023, 49 (01) : 19 - 43
  • [23] Cardiovascular comorbidity in rheumatic diseases
    Nurmohamed, Michael T.
    Heslinga, Maaike
    Kitas, George D.
    NATURE REVIEWS RHEUMATOLOGY, 2015, 11 (12) : 693 - 704
  • [24] The cardiovascular manifestations of rheumatic diseases
    Goodson, NJ
    Solomon, DH
    CURRENT OPINION IN RHEUMATOLOGY, 2006, 18 (02) : 135 - 140
  • [25] Autoimmune Rheumatic Diseases and Premature Atherosclerotic Cardiovascular Disease: An Analysis From the VITAL Registry
    Mahtta, Dhruv
    Gupta, Angela
    Ramsey, David J.
    Al Rifai, Mahmoud
    Mehta, Anurag
    Krittanawong, Chayakrit
    Lee, Michelle T.
    Nasir, Khurram
    Samad, Zainab
    Blumenthal, Roger S.
    Jneid, Hani
    Ballantyne, Christie M.
    Petersen, Laura A.
    Virani, Salim S.
    AMERICAN JOURNAL OF MEDICINE, 2020, 133 (12) : 1424 - +
  • [26] Carotid Artery Pathology in Inflammatory Diseases
    Rodriguez, Tayana
    Lehker, Angelica
    Mikhailidis, Dimitri P.
    Mukherjee, Debabrata
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2022, 363 (03) : 209 - 217
  • [27] Disease activity after the discontinuation of biological therapy in inflammatory rheumatic diseases
    Gabriella Kádár
    Erika Balázs
    Boglárka Soós
    Anita Laduver
    Péter Keszthelyi
    Zoltán Szekanecz
    László Kovács
    Clinical Rheumatology, 2014, 33 : 329 - 333
  • [28] The Importance of Outcome Measures in the Management of Inflammatory Rheumatic Diseases
    Collada, Juan Molina
    Trives, Laura
    Castrejon, Isabel
    OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS, 2021, 13 : 191 - 200
  • [29] Disease activity after the discontinuation of biological therapy in inflammatory rheumatic diseases
    Kadar, Gabriella
    Balazs, Erika
    Soos, Boglarka
    Laduver, Anita
    Keszthelyi, Peter
    Szekanecz, Zoltan
    Kovacs, Laszlo
    CLINICAL RHEUMATOLOGY, 2014, 33 (03) : 329 - 333
  • [30] Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project
    Castaneda, Santos
    Martin-Martinez, Maria A.
    Gonzalez-Juanatey, Carlos
    Llorca, Javier
    Garcia-Yebenes, Maria J.
    Perez-Vicente, Sabina
    Sanchez-Costa, Jesus T.
    Diaz-Gonzalez, Federico
    Gonzalez-Gay, Miguel A.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2015, 44 (06) : 618 - 626